Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | completed | Phase 1 | 6 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00354926 | Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma | completed | Phase 1 | 67 | Applied Molecular EvolutionINDUSTRY | 1 | Jan 7, 2016 | clinicaltrials |
| NCT00141297 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | completed | Phase 1 | 74 | PfizerINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00588328 | The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00002818 | High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies | completed | Phase 1 | 15 | Virginia Commonwealth UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT00001575 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | completed | Phase 1 / Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00693433 | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01276717 | Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma | completed | Phase 1 | 20 | University of RochesterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT01421173 | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | completed | Phase 1 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00561756 | Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00893464 | A Study of IXAZOMIB in Adult Patients With Lymphoma | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Nov 11, 2015 | clinicaltrials |
| NCT01902160 | Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01588548 | Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | completed | Phase 1 | 43 | AstraZenecaINDUSTRY | 2 | Nov 4, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00127140 | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 28, 2015 | clinicaltrials |
| NCT00916630 | Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00364676 | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 1 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Sep 22, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01435863 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 | 17 | Solasia Pharma K.K.INDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00045513 | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00561418 | Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma | completed | Phase 1 | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00413075 | Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 121 | Valerio TherapeuticsINDUSTRY | 3 | Jul 8, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00947739 | Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 43 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 18, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01602289 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00007956 | Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00020462 | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00045500 | UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2016source: clinicaltrials